Lexicon Pharmaceuticals (LXRX) Announces 22% Reduction in Workforce
More News related to LXRX
- Thomas Weisel Starts Lexicon (LXRX) at Overweight, $2.50 Price Target
- Lexicon Pharma (LXRX) to Present LX1031 Phase 2 Results at GASTRO 2009
- Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
- Morning Movers 11/13: CNIC, TSTC, NLST, AGO, SLI Higher; LIME, GMET, BIOF, DISK, MRGE, SSY Lower
- After-Hours Movers 11/12: TSTC, LXRX, MDSO Higher; DISK, MRNA, LIME, BBI, ESE, JWN Lower
More News related to Corporate News
- Trading Radar for 12/7: Kroger (KR), Pep Boys (PBY), Krispy Kreme (KKD), Casey's General Stores (CASY) Report
- Unusual 11 Mid-Day Movers 12/04: BIG, FLOW, SNV, OCLS Higher; TTWO, ZIOP, VSNT, SWHC Lower
- Notable ETF Movers 12/04: UUP, UNG Up; XME, GDX, GLD, SLV Down
- Notable Analyst Rating Changes 12/04: BAC, SNV, FSLR, AKAM Upgraded; TTWO, SWHC, AKS, NFLX Downgraded
- Morning Movers 12/04: OCLS, FLOW, BIG, LOGC, PEIX Higher; TTWO, STE, BCON, VSNT, ZIOP, SWHC Lower
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announceda restructuring of its operations to conserve capital and direct resources towards its most advanced drug discovery and development programs. The restructuring will involve a workforce reduction of 102 employees, primarily in basic research, early-stage discovery and support positions, representing approximately 22% of its total workforce.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
